Literature DB >> 3049614

World Health Organization International Standards for highly purified human, porcine and bovine insulins.

A F Bristow1, R E Das, D R Bangham.   

Abstract

The 4th International Standard (IS) for Insulin, established in 1958, consists of a mixture of relatively impure bovine and porcine insulins and is not suitable as a standard for the assay of highly purified single-species insulins presently used in the treatment of diabetes. Preparations of human, bovine and porcine crystalline insulins, representative of current highly purified therapeutic insulins, have now been studied in an international collaborative study carried out by twenty-three laboratories in fifteen countries. In the collaborative study described here, each of the three preparations was found to be suitable for use as a standard for insulin for bioassay and each was established by WHO in 1986 as an international standard. The 4th IS of Insulin bovine/porcine (code numbered 58/6) has been discontinued. Insulin preparations should now be calibrated in terms of International Units defined by the standard for the appropriate species: the International Standard for Insulin, Human, the International Standard for Insulin, Bovine, or the International Standard for Insulin, Porcine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049614     DOI: 10.1016/0092-1157(88)90004-2

Source DB:  PubMed          Journal:  J Biol Stand        ISSN: 0092-1157


  3 in total

1.  Insulin Units and Conversion Factors: A Story of Truth, Boots, and Faster Half-Truths.

Authors:  Jennifer L Knopp; Lui Holder-Pearson; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2018-10-13

Review 2.  Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia.

Authors:  Diva D De León; Charles A Stanley
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-07-09       Impact factor: 4.690

3.  Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes.

Authors:  April L Darrow; Ralph V Shohet
Journal:  Cardiovasc Diabetol       Date:  2015-06-06       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.